{
    "nct_id": "NCT06094010",
    "official_title": "A Phase IIIb Multicenter, Single-Arm, Open-Label Surveillance Study of Susceptibility to Baloxavir Marboxil in Patients With Influenza",
    "inclusion_criteria": "* Participants with symptoms suggestive of influenza with diagnosis confirmed by a positive local influenza test within 24 hours before full study screening.\n* Participants with a negative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test within 48 hours before full study screening.\n* Time interval between onset of influenza symptoms and the pre-dose examinations at screening is 48 hours or less\nHealthy volunteers allowed\nMust have minimum age of 1 Year\nMust have maximum age of 11 Years",
    "exclusion_criteria": "* Participants with severe influenza virus infection requiring inpatient treatment.\n* Severely immunocompromised participants [including participants receiving immunosuppressant therapy, or those with cancer or human immunodeficiency virus (HIV) infection] as defined by the investigator.\n* Participants with concurrent (non-influenza) infections requiring systemic anti-microbial and/or anti-viral therapy at the pre-dose examinations.\n* Treatment with baloxavir marboxil, peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir or amantadine within 30 days prior to screening.\n* Treatment with an investigational influenza-specific monoclonal antibody within 6 months or 5 half-lives, whichever is longer, prior to screening.\n* Treatment with an investigational therapy within 30 days or 5 half-lives, whichever is longer, prior to screening.\n* Known hypersensitivity to baloxavir marboxil or the drug product excipients.\n* Females who have commenced menarche (i.e., child-bearing potential).",
    "miscellaneous_criteria": ""
}